Skip Navigation LinksHome > November 28, 2013 - Volume 27 - Issue 18 > In-vitro phenotypic susceptibility of HIV-1 ’non-B’ integras...
AIDS:
doi: 10.1097/QAD.0000000000000016
Research Letters

In-vitro phenotypic susceptibility of HIV-1 ’non-B’ integrase inhibitors naive clinical isolates to dolutegravir and raltegravir

Charpentier, Charlottea,b; Bertine, Mélaniea,b; Visseaux, Benoita,b; Leleu, Juliettea,b; Larrouy, Lucilea,b; Peytavin, Gillesa; Mourez, Thomasc; Collin, Gillesa,b; Brun-Vézinet, Françoisea,b; Plantier, Jean-C.b,c; Descamps, Dianea,b

Collapse Box

Abstract

In this study, we assessed phenotypic susceptibility to dolutegravir and raltegravir in a large variety of HIV-1 ‘non-B’ subtypes (n = 72) issued from integrase inhibitor-naive clinical isolates. All samples were susceptible to both dolutegravir and raltegravir with median IC50 values of 1.22 nmol/l and 1.53 nmol/l, respectively; similar to that observed for the B subtype. Thus, despite the high prevalence of polymorphic substitutions in integrase in ‘non-B’ clinical isolates, phenotypic susceptibility to dolutegravir remained unchanged.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login